Urothelial carcinoma is the most common bladder cancer, with stage 1 indicating early-stage disease confined to the bladder lining. Diagnosis involves urinalysis, cystoscopy, TURBT, and imaging to ...

Distinguishing cancer cells from healthy cells is a central challenge in cancer treatment. Ideal therapies selectively kill cancer cells while leaving healthy cells healthy and able to perform their ...

From bladder to upper urinary tract: Unveiling the epidemiological dynamics of urothelial carcinoma. Clinical burden of recurrence among older adults with muscle invasive bladder cancer undergoing tri ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Since the 1970s, the mainstay of treatment for urothelial carcinoma (UC) has been platinum-based chemotherapy. Treatment-associated toxicity, however, has limited efficacy, leaving survivors with ...

Astellas Pharma India today announced that PADCEV™ (enfortumab vedotin) in combination with pembrolizumab is now approved for ...

Astellas Pharma India has announced that the Central Drugs Standard Control Organisation (CDSCO) has approved PADCEV ...

Germline DNA repair gene (gDRG) variants in BCG un-responsive patients: A potential genetic implication for risk stratification and target therapy. This is an ASCO Meeting Abstract from the 2026 ASCO ...

The Scottish Medicines Consortium has approved a new first-line combination therapy for restricted use in adults with unresectable or metastatic urothelial cancer.

They further applied two-sample Mendelian randomization (TSMR) analysis to examine genetic associations between prostate cancer and ten common secondary primary malignancies (SPMs). The study not only ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today ...